U.S. Markets closed

Grifols, S.A. (GRF.MC)


MCE - MCE Delayed Price. Currency in EUR
Add to watchlist
26.245-0.55 (-2.07%)
At close: 5:35PM CEST
Full screen
Previous Close26.800
Open26.750
Bid25.920 x 68800
Ask26.500 x 1500
Day's Range26.245 - 26.970
52 Week Range16.480 - 26.970
Volume429,509
Avg. Volume1,175,075
Market Cap16.32B
Beta0.85
PE Ratio (TTM)32.05
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield0.54 (1.85%)
Ex-Dividend Date2016-12-05
1y Target EstN/A
  • When 'New' Means A Stock Hasn't Led The Market In A While
    Investor's Business Daily4 days ago

    When 'New' Means A Stock Hasn't Led The Market In A While

    Celgene and Grifols are former leaders, but enough time has passed to give them a new shine.

  • Should Value Investors Consider Grifols (GRFS) Stock Right Now?
    Zacks9 days ago

    Should Value Investors Consider Grifols (GRFS) Stock Right Now?

    Is Grifols a great pick from the value investor's perspective right now? Read on to know more.

  • American City Business Journals2 months ago

    Can young blood pump new life into treatments for diseases of aging?

    Young blood loaded with a particular protein, which is less plentiful as people age, could rejuvenate learning and memory, Stanford University researchers said in a paper released today. It would take even longer to make drugs that mimic the protein. Ultimately, San Carlos' Alkahest Inc., which has rights to license the research, and Barcelona-based Grifols S.A. (GRFS) could market treatments aimed at age-associated declines in learning skills and memory, but not necessarily targeting memory-robbing Alzheimer's disease.